GEPRE: Un Sistema de Gestión Presupuestaria para una mayor democratización del Presupuesto en la Universidad

GEPRE es más que un software; representa una metodología y un conjunto de técnicas aplicadas que permite la discusión, elaboración y seguimiento del presupuesto participativo por actividad, en el marco amplio de los actores responsables de actividades en la Universidad Nacional de Cuyo. El mismo abarca la gestión Rectoral de la Dra. María Victoria Gómez de Erice y del Ing. Arturo Somoza, enmarcado en una visión amplia y de activa participación de todos los integrantes de la comunidad universitaria. Donde ninguno de ellos escapa a obligaciones y derechos concernientes a sus responsabilidades al momento de ejecutar tareas que deben haber sido planificadas cuidadosamente y reunidas en Actividades, convertidas en valores económicos, sociales y humanos que requieren de recursos presupuestarios, los que a su vez deben ser acordados por todos los actores intervinientes en dicho proceso. Los roles de dichos actores en el sistema presupuestario de la universidad permite clarificar y transparentar la discusión presupuestaria, su ejecución y el control pertinente. Mediante un ambiente colaborativo, plataforma GEPRE, desarrollado con herramientas de software libre, asegurando la interacción con el resto de los sistemas que poseen datos indispensables para que los Usuarios logren el presupuesto de la Universidad.GEPRE is more that a software; it represents a methodology and a group of technicians applied, that allows the discussion, production and follow-up of the participative budget by activity, in the wide frame of the responsible actors of activities in the National University of Cuyo. The same range the management rectorial of the Dr María Victoria Gómez of Erice and of the Ing. Arturo Somoza, framed in a wide vision and a active participation of all the members of the university community. Where none of them escape to obligations and right relating to their responsibilities in the moment to execute tasks that should have been scheduled carefully and assembled in activities, converted in economic values, social and human that require of budgetary resources, those at the same time, must be agreed by all actors’ interveners in the process. Finally the roles that said actors act in the budgetary system of the university allows to classify and does visible the budgetary discussion, its execution and the pertinent control. By means of a collaborative environment, platform GEPRE, developed with tools of free software, that ensures the interaction with the rest of the systems that possess indispensable data so that the users attain the budget of the University.Sociedad Argentina de Informática e Investigación Operativ

Uso de Microtomografía de rayos X para la identificación de daños en semillas de soja

Por ser un método no destructivo, las semillas analizadas con micro-TC pueden ser sometidas a pruebas fisiológicas, con la finalidad de establecer patrones que permitan estudiar la relación causaefecto de la presencia de distintos daños en las semillas. La Prueba topográfica por Tetrazolio (TZ) es una prueba bioquímica que puede ser utilizada para hacer una rápida estimación de la viabilidad y vigor de las semillas y para detectar la presencia de daños causados por distintos factores como el ambiente de producción, las picaduras de chinches y maquinarias (ISTA, 2022). El objetivo del trabajo fue identificar daños en semillas de soja (Glycine max L.) mediante el uso de microtomografías de rayos X y comparar con los resultados la Prueba topográfica por Tetrazolio.EEA OliverosFil: Gallo, Carina Del Valle. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Oliveros. Laboratorio de Semillas; ArgentinaFil: Martinez, Mailen Ariela. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Oliveros; ArgentinaFil: Martinez, Mailen Ariela. Universidad Nacional de Rosario. Facultad de Ciencias Agrarias. Departamento de Fisiología Vegetal; ArgentinaFil: Arango, Miriam Raquel. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Oliveros. Laboratorio de Semillas; ArgentinaFil: Rubino, Guillermo. Instituto Nacional de Tecnología Industrial Rafaela (INTI Rafaela). Departamento de Validación de Equipos y Componentes; ArgentinaFil: Peralta, Matías. Instituto Nacional de Tecnología Industrial Rafaela (INTI Rafaela); ArgentinaFil: Airaldo, Gastón. Instituto Nacional de Tecnología Industrial Rafaela (INTI Rafaela); Argentin

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Background: Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes. Methods: In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-calorie diet and increased physical activity. Time to diabetes onset by 160 weeks was the primary outcome, evaluated in all randomised treated individuals with at least one post-baseline assessment. The trial was conducted at 191 clinical research sites in 27 countries and is registered with ClinicalTrials.gov, number NCT01272219. Findings: The study ran between June 1, 2011, and March 2, 2015. We randomly assigned 2254 patients to receive liraglutide (n=1505) or placebo (n=749). 1128 (50%) participants completed the study up to week 160, after withdrawal of 714 (47%) participants in the liraglutide group and 412 (55%) participants in the placebo group. By week 160, 26 (2%) of 1472 individuals in the liraglutide group versus 46 (6%) of 738 in the placebo group were diagnosed with diabetes while on treatment. The mean time from randomisation to diagnosis was 99 (SD 47) weeks for the 26 individuals in the liraglutide group versus 87 (47) weeks for the 46 individuals in the placebo group. Taking the different diagnosis frequencies between the treatment groups into account, the time to onset of diabetes over 160 weeks among all randomised individuals was 2·7 times longer with liraglutide than with placebo (95% CI 1·9 to 3·9, p<0·0001), corresponding with a hazard ratio of 0·21 (95% CI 0·13–0·34). Liraglutide induced greater weight loss than placebo at week 160 (–6·1 [SD 7·3] vs −1·9% [6·3]; estimated treatment difference −4·3%, 95% CI −4·9 to −3·7, p<0·0001). Serious adverse events were reported by 227 (15%) of 1501 randomised treated individuals in the liraglutide group versus 96 (13%) of 747 individuals in the placebo group. Interpretation: In this trial, we provide results for 3 years of treatment, with the limitation that withdrawn individuals were not followed up after discontinuation. Liraglutide 3·0 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes. Funding: Novo Nordisk, Denmark

New insights into the genetic etiology of Alzheimer's disease and related dementias

Characterization of the genetic landscape of Alzheimer's disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/'proxy' AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele

Common variants in Alzheimer's disease and risk stratification by polygenic risk scores.

Funder: Funder: Fundación bancaria ‘La Caixa’ Number: LCF/PR/PR16/51110003 Funder: Grifols SA Number: LCF/PR/PR16/51110003 Funder: European Union/EFPIA Innovative Medicines Initiative Joint Number: 115975 Funder: JPco-fuND FP-829-029 Number: 733051061Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer's disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer's disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer's disease

Multiancestry analysis of the HLA locus in Alzheimer’s and Parkinson’s diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes

Across multiancestry groups, we analyzed Human Leukocyte Antigen (HLA) associations in over 176,000 individuals with Parkinson’s disease (PD) and Alzheimer’s disease (AD) versus controls. We demonstrate that the two diseases share the same protective association at the HLA locus. HLA-specific fine-mapping showed that hierarchical protective effects of HLA-DRB1*04 subtypes best accounted for the association, strongest with HLA-DRB1*04:04 and HLA-DRB1*04:07, and intermediary with HLA-DRB1*04:01 and HLA-DRB1*04:03. The same signal was associated with decreased neurofibrillary tangles in postmortem brains and was associated with reduced tau levels in cerebrospinal fluid and to a lower extent with increased Aβ42. Protective HLA-DRB1*04 subtypes strongly bound the aggregation-prone tau PHF6 sequence, however only when acetylated at a lysine (K311), a common posttranslational modification central to tau aggregation. An HLA-DRB1*04-mediated adaptive immune response decreases PD and AD risks, potentially by acting against tau, offering the possibility of therapeutic avenues